Gladius Capital Management LP Emergent Bio Solutions Inc. Transaction History

Gladius Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Dec 18, 2023	BUY	$7.35 - $13.21 $18,316 - $32,919	2,492 New	2,492 $18,000
Q2 2023 Aug 08, 2023	SELL	$7.35 - $13.21 $1,594 - $2,866	-217 Reduced 8.01%	2,492 $19,000
Q1 2023 Dec 18, 2023	BUY	$7.79 - $16.29 $21,103 - $44,129	2,709 New	2,709 $28,000
Q1 2023 May 09, 2023	SELL	$7.79 - $16.29 $3,147 - $6,581	-404 Reduced 12.98%	2,709 $29,000
Q4 2022 Dec 18, 2023	BUY	$11.0 - $21.45 $34,243 - $66,773	3,113 New	3,113 $36,000
Q4 2022 Feb 02, 2023	BUY	$11.0 - $21.45 $16,841 - $32,839	1,531 Added 96.78%	3,113 $37,000
Q3 2022 Nov 14, 2022	BUY	$20.09 - $35.8 $31,782 - $56,635	1,582 New	1,582 $34,000

160

33.8M

453K

931K

Ticker EBS
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,861,500
Market Cap $438M
Description
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.